Investors are targeting discovery and platform-stage assets as long-term strategic bets to secure innovation pipelines for the next decade
Pregnancy Outcomes After Semaglutide Exposure
Cardiovascular and Endothelial Benefits GLP-1 RAs have demonstrated robust cardiovascular protection in multiple large-scale trials, including LEADER, REWIND, and SUSTAIN-6, showing reduced rates of major adverse cardiac events independent of weight loss
Compared to HAMS, HAMSB exhibited a reduced vulnerability to in vitro amylolysis after the cooking process [99], indicating increased stability and a higher delivery rate
Giblin et al., Diabetes Obes Metab 2026 (trial design paper) Note: Some media reports cite NCT05869903 for TRIUMPH-4
How might a diabetes drug help treat Parkinsons